
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
ZC3H4 (zinc finger CCCH-type containing 4) encodes a member of the CCCH-type zinc finger protein family. Its zinc finger domain is capable of nucleic acid binding, consistent with a role in RNA- or DNA-associated regulation. ZC3H4 is involved in transcriptional regulation and may contribute to post-transcriptional control of gene expression through interactions with nucleic acids and regulatory proteins.
NCI-H1299 is a human non-small cell lung cancer cell line established from a lymph node metastasis of the lung from a patient who had previously received radiation therapy. The cell line represents a metastatic lung cancer model and is commonly used in studies of lung cancer biology, tumor progression, and molecular mechanisms underlying cancer development.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 3
Reference Transcript: NM_015168
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?